Evidence map›Paper›PMID 37131904›Full record

ArticleReports of biochemistry & molecular biology2023

The Use of Chitosan Nanoparticles for Delivery of CpG ODN in Treatment of Allergic Balb/C Mice.

Febriana Catur Iswanti, Qarina Hasyala Putri, Ani Retno Prijanti, Samsuridjal Djauzi, Mohamad Sadikin, Arief Budi Witarto, Tomohiko Yamazaki

Abstract read
In one paragraph

Article in Reports of biochemistry & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Febriana Catur IswantiDepartment of Biochemistry and Molecular Biology Faculty of Medicine, Universitas Indonesia, Indonesia.
Qarina Hasyala PutriMaster's Programme in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Indonesia.
Ani Retno PrijantiDepartment of Biochemistry and Molecular Biology Faculty of Medicine, Universitas Indonesia, Indonesia.
Samsuridjal DjauziDepartment of Internal Medicine, Faculty of Medicine, Ciptomangunkusumo Hospital, Universitas Indonesia, Indonesia.
Mohamad SadikinDepartment of Biochemistry and Molecular Biology Faculty of Medicine, Universitas Indonesia, Indonesia.
Arief Budi WitartoDepartment of Molecular Biology and Cell, Faculty of Medicine, Indonesia Defense University, Indonesia.
Tomohiko YamazakiResearch Center for Functional Materials, National Institute for Materials Science (NIMS), Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to prepare high stability chitosan nanoparticles (CNP) and examine the ability of CNP in CpG-ODN delivery when treating allergic mice model. Methods: Preparation and characterization of CNP were performed by ionic gelation, dynamic light scattering, and zeta sizer. The CNP cytotoxicity and activation ability of CpG ODN delivered with CNP were tested using a cell counting kit-8 and Quanti blue method. Allergic mice were injected intraperitoneal with 10 ug ovalbumin on day 0 and 7, and then treated with intranasal CpG ODN/CpG ODN, delivered with CNP/CNP, on the third week three times per week for three weeks. The ELISA method measured cytokine and IgE profiles in the allergic mice's plasma and spleen. Results: CNP results have sizes 27.73 nm±3.67 dan 188.23 nm±53.47, spherical in shape and non-toxic, and did not alter the NF-κB activation of CpG ODN in RAW-blue cells. The application of CpG ODN delivered by chitosan nanoparticles shows no statistical difference between groups of IFN-γ, IL-10, and IL-13 in Balb/c mice's plasma and spleen, in contrast with IgE level. Conclusions: The results showed that using chitosan nanoparticles as a delivery system for CpG ODN has the potency to safely CpG ODN efficacy.

Indexed as

AllergyChitosan nanoparticleCpG ODNImmunotherapyMice spleen

Identifiers

PMID37131904
PMCPMC10149129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.